Comparative Pharmacology
Head-to-head clinical analysis: R P MYCIN versus WYAMYCIN E.
Peer-Reviewed Evidence
Head-to-head clinical analysis: R P MYCIN versus WYAMYCIN E.
R-P MYCIN vs WYAMYCIN E
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
R-P MYCIN is a macrolide antibiotic that inhibits bacterial protein synthesis by binding to the 50S subunit of the bacterial ribosome, specifically at the 23S rRNA of the peptidyl transferase center. This action blocks the translocation step, thereby preventing the elongation of the peptide chain.
Aminoglycoside antibiotic that binds to the 30S ribosomal subunit, causing misreading of mRNA and inhibiting bacterial protein synthesis.
Rifampin 600 mg orally once daily or 10 mg/kg intravenously once daily.
500 mg intramuscularly or intravenously every 12 hours; or 1 gram every 24 hours for severe infections.
None Documented
None Documented
Terminal half-life 2-3 hours; prolonged in renal impairment (up to 6-8 hours in anuria).
2.5 hours (increased to 5-8 hours in neonates and up to 24-48 hours in anuria).
Renal (60-80% unchanged), biliary/fecal (15-20%).
Primarily renal (60-80% unchanged) via glomerular filtration; biliary/fecal <5%.
Category C
Category C
Macrolide Antibiotic
Macrolide Antibiotic